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1 
The effects of antiepileptics(phenobarbital sodium， valproate sodium)， GABA-
mimetic(vigabatrin) and N-methyl-D-aspartic acid(NMDA) receptor antagonists(CPP， MK-
801) were studied on NMDA -induced convulsions following intraperitoneal and 
intraventricular administration in mice and rats. 
Phenobarbital sodium， valproate sodium， CPP and MK -801 prevented NMDA -induced 
convulsions， but these drugs showed more sensitive activities for intraventricular than 
intraperitoneal NMDA -induced convulsions. 
Vigabatrin did not affect to Nν1DA-induced convulsions， moreover， didn't potentiated the 
anticonvulsant activities of CPP and MK-801. 
The stages of kindled seizure were suppressed slightly by CPP and vigabatrin， and 
significantly by MK -801. The durations of afterdischarge were reduced by CPP， but were 
not influenced by MK -801 and vigabatrin. 
The combined use of vigabatrin with CPP and MK -801 increased the effects of CPP and 
MK -801 on the stages of kindled seizure， but not on the durations of afterdischarge. 
Based on these results obtained， the characteristics of NMDA -induced convulsions and 
action mechanism of anticonvulsants on NMDA -induced convulsions and amygdala kindled 
























-dihydro-5H-dibenzo (a， d)cyclohepten-5， 10-
imine maleate)とCPP(3-((こと)一2-carboxypiper-











































































stage 1 : mouth and facia1 movements 
stage 2 : head nodding 
stage 3 : forelimb clonus 
stage 4 rearing 











































NMDA(Sigma Chemica1 Co.， U.S.A.)， 
phenobarbita1 sodium(三共)， va1proate 
sodium(協和発酵)， vigabatrin(Merrell Dow 
Pharmaceutica1s Inc. U.S.A.)， MK-

































































































1 ) phenobarbital sodium 
1群10-20匹のマウスを用い， phenobarbital 










2) valproate sodium 









3 ) vigabatrin 













(mg/kg) MF CL TF TE 計(%)
対照 27 16 2 (6) 1 ( 9) 3 (12) 22 ( 82) 22 (22) 
20 10 6 1 (3) 1 1 ( 2) 9 ( 90) 8 ( 9)
phenobarbital N a 50 20 6 3 (2) o ( 2) I( 2) 10( 50)* 7 (18) 
100 16 4 1 O o ( 1) 5 ( 31)村 1 (15) 
valproate Na 
500 15 8 5(4) o ( 8) o ( 4) 13 ( 87) 12 (15) 
800 14 1 2 (1) O O 3 ( 21) * 3 (11) 
300 10 8 1 (6) O I( 7) 10 (100) 10 (10) 
vigabatrin 500 18 15 O 0(11) 2 (11) 17 ( 94) 17 (17) 
1000 12 8 0(6) o ( 8) 2 ( 6) 10 ( 83) 10 (10) 
0.2 15 4 5 (3) 2 ( 4) 1 ( 3) 12 ( 80) 12 (14) 
MK-801 0.5 14 4 0(3) O 3 7 ( 50)本 7 (12) 
1.0 14 8 0(3) 1 ( 1) O 9 ( 64) 2 (12) 
5 20 8 5 (5) 2 ( 4) o ( 9) 15 ( 75) 14 (15) 
Cpp 10 20 4 2 (1) o ( 2) I( 2) 7 ( 35)村 7 ( 9)
15 11 4 O O o ( 1) 4( 36)** 1 ( 3)
20 11 2 0(1) O O 2 ( 18)判 I( 2) 
vigabatrin 300 
十MK-801 1.0 12 5 O O I 6 ( 50) * 2 ( 7)
十Cpp 10 12 4 0(1) o ( 2) O 4 ( 33)件 4 ( 5)
vigabatrin 500 
十MK-801 0.5 11 2 5 (1) o ( 2) 8 ( 73) 6 ( 8)

































(mg/kg) CL TF TE 計(%)
対照 37 5 25 (2) 2 (27) 32 ( 86) 21 (21) 
10 6 2 4 (1) o ( 5) 6 (100) l( 1) 
phenobarbital N a 20 10 3 O 2 5 ( 50) * 1 ( 1) 
30 10 O O O O( 0)** o ( 1) 
100 10 4 6 (4) 0(10) 10 (100) 4 ( 4)
valproate N a 300 10 1 6 l( 6) 8 ( 80) 3 ( 7)
500 10 1 4 o ( 3) 5 ( 50) * 1 ( 2) 
vigabatrin 500 11 O 10 0(10) 10 ( 91) 5 ( 5)
0.1 10 1 6 (1) o ( 6) 7 ( 70) 1 ( 1)
MK-801 0.2 10 3 2 (2) l( 1) 6 ( 60) * 1 ( 1)
0.5 10 1 1 o ( 1) 2(20)** l( 2) 
l 6 2 3 (2) 1 ( 3) 6 (100) 4 ( 4)
Cpp 2 10 1 7 o ( 7) 8 ( 80) 4 ( 4)
5 10 3 2 (2) l( 4) 6 ( 60) * 1 ( 2) 
10 10 O 2 o ( 2) 2(20)** o ( 1) 
vigabatrin 500 
0.1 10 2 6 o ( 6) 8 ( 80) 5 ( 6)
+MK-801 0.2 10 2 4(1) o ( 4) 6 ( 60)本 3 ( 3)
0.5 10 1 2 o ( 1) 3 ( 30)料 1 ( 1)
2 8 1 6 (1) o ( 7) 7 ( 88) o ( 0) 
十CPP 5 10 O 9 o ( 8) 9 ( 90) o ( 0) 






















1 ) phenobarbital sodium 
1群 6-10匹のマウスを用い phenobarbital








2) valproate sodium 
l群10匹のマウスを用いvalproatesodium 






















1群 6-10匹のマウスにCPP 1， 2， 5および
10mg/kgを腹腔内投与し， 50分後に NMDA1，ug/ 
動物を側脳室内に注入した.
結果は表3に示すとおり， 1および2mg/kgの投
与ではほとんど抗けいれん作用はみられず， 5 mg/ 











併用によってもそれぞれ10例中 2例， 4例， 7例と
ほとんど変わらず，併用による影響は認められな
かったが，死亡例については MK-8010.1， 0.2mg/ 
kg投与群で、むしろ増加傾向を示した.
CPP 2， 5， 10mg/kg膿腔内投与によるけいれん
抑制作用は，単独応用の場合にはそれぞれ10例中
2例， 4例， 8例に認められたものが， vigabatrin 










































が， 5 mg/kgで、は投与前9l.7秒が投与後57.0秒， 10 
mg/均投与で、は投与前7l.1秒が投与後47.3秒とな
り有意な短縮が認められた.
3 ) vigabatrin 





















ADの持続に対しては， MK -801 O. 5mg/kgは単











(時/kg) 投与蔀 投与後 投与前 投与後
0.9%Nacl 9 76.1土 8.6 77.3ごと 9.9 5.0:!::0 5.0土O
MK-801 0.5 
6 83.0:!:: 6.5 65.7土 8.2 5.0土O 2.3:!::0.2料
l.0 6 99.5土1l.0 9l.5:!::10.3 5.0土O l.5土0.2**
1 6 84.8土 7.9 87.2:!: 6.5 5.0土O 5.0土 O 
cpp 5 6 9l. 7士 7.1 57.0土12.2* 5.0:!::0 3.2ごと0.7
10 7 7l.1ごと 6.1 47.3土 8.9* 5.0:!::0 3.4土0.8
.ab t . 300 6 102.8:!:: 9.2 115.3ごと19.2 5.0土O 3.3:!::0.6* vlgaOatnn 500 7 94.4:!:: 9.7 92.3土16.7 5.0土O 3.1:!::0.8 
vigabatrin 300 
十MK-801O .5 6 93.2ごと10.4 48.0土11.7* 5.0:!::0 l.7ごと0.3**
l.0 6 115.0ごと 5.6 94.5:!::22.3 5.0:!::0 l.3ごと0.3村
+cpp 5 6 103.5:!:: 5.4 68.5土20.8 5.0:!::0 l.8:!::0.4** 
10 6 107.3:!:: 9.3 79.2土30.0 5.0土O l.5:!::0.6** 
vigabatrin 500 
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A:対照 B: NMDA 25rng/kg静注4分後，


























































































































































































































































































































































1) Cain， D.P. (1986). Amygda10id kindling is 
retarded by an antagonist of excitatory 
amino acid receptors， DL-2-amino-5-
phosphonova1eric acid. Soc N eurosci 
Abstr 12， 69. 
2) Chapman， A. G.， Me1drum， B. S.， Nanji， 
N. and Watkins， J.C. (1987). Anticonvu1-
sant action and biochemica1 effects in 
DBA/2 mice of CPP(3-((土)-2-carbox-
ypiperazin-4-yl)-propy1-1-phosphonate)， a 
nove1 N -methy 1-D-asparta te antagonist. 
Eur J Pharmaco1 139， 91-96. 
3) Clineschmidt， B. V.， Martin， G. E. and 
Bunting， P. R. (1982). Anticonvu1sant 
activity of (+ )-5-methy1-10，11-dihydro-
5H -dibenzo [a，d] cyc10hepten -5， 10-
imine(MK -801)， a substance with potent 
anticonvu1sant， centra1 sympathomimetic， 
and apparent anxio1ytic properties. Drug 
Dev 1ミes2， 123-134. 
4) Croucher， M. ].， Colling， J. F. and 
Me1drum， B. S. (1982). Anticonvu1sant 
action of excitatory amino acid antago-
nists. Science 216， 899-901. 
5) Czuczwar， S.].， Frey， H.-H. and Lδscher， 
W. (1985). Antagonism of N-methy1-D，L 
aspartic acid -induced convu1sions by 
antiepileptic drugs and other agents. Eur 
J Pharmaco1 108， 273-280. 
6) Fabisiak， J.P. and Schwark， W. S. (1982). 
Cerebra1 free amino acids in the amyg-
da10id kind1ing mode1 of epilepsy. Neuro-
pharmaco1 21， 179-182. 
7) Gang1off，百.and Monnier， M. (1957). The 
action of anticonvu1sant drugs tested by 
e1ectrica1 stimu1ation of the cortex， dien-
cepha10n and rhinencepha10n in the 
unanesthetized rabbit. E1ectroencepha1ogr 
C1in Neurophysio1 9， 43-58. 
8) Goddard， G. V. (1967). Deve10pment of 
epileptic seizures through brain stimu1a幽
tion at 10w intensity. Nature 214， 1020-
1021. 
9) Gram， L.， K1osterskov， P. and Dam， M. 
(1985).γ-Viny1 GABA: A doub1e-blind 
p1acebo-controlled tria1 in partia1 epi-
1epsy. Ann Neuro1 17， 262-266. 
10) Ha1ey， T. J. and McCormick，羽T. G. 
(1957). Pharmaco1ogica1 effects produced 
intracerebra1 injection of drugs in the 
conscious mouse. Br J Pharmaco1 12， 12… 
15. 
11) Ho1mes， K. H. and Goddard， G. V. (1986). 
14 木下ゆか子
A role for the N-methyl-D-aspartate 
receptor in kindling. Proc Univ Otago 
Med Sch 64， 37-38. 
12) Joy， R. M.， Albertson， T. E. and Stark， L. 
G. (1984). An analysis of the actions of 
progabide， a specific GABA receptor 
agonist， on kindling and kindled seizures. 
Exp Neurol 83， 144-154. 
13) Jung， M. J.， Lippert， B.， Metcalf， B. W.， 
Bohlen， P.and Schechter， P. J. (1977).γ 
-Vinyl GABA(4-amino-hex-5-enoic acid)， 
a new selective irreversible inhibitor of 
GABA-T:Effects on brain GABA metabo-
lism in mice. J Neurochem 29， 797-802. 
14) Kalichman， M. W.， Burnham， W. M. and 
Livingston， K. E. (1982). Pharmacological 
investigation of gamma -aminobutylic 
acid(GABA) and fully-developed general-
ized seizures in the amygdala-kindled rat. 




ンポジウム 15( 1 )， 14-30. 
16)君島健次郎，田辺恭子(1990).抗てんかん薬
(抗癌壁薬).斉藤洋，野村靖幸編，医薬品
の開発第9巻，医薬品の探索 1， pp. 51 
-67.藤川書庖，東京.
17) Konig， J.F. R. and Klippel， R. A. (1967). 
The rat brain， Robert E. Krieger Publish-
ing Co.， Hamburg. 
18) Leach， M. J.， Miller， A. A.， O'Donnell， R. 
A.， Webster， R. A. and Weston， S. B. 
(1981). Effect of electrical kindling on 
brain amino acid concentrations in rats. 
Br J Pharmacol 74， 883-884. 
19) Le Gal La Salle， G. (1980). Inhibition of 
kindling-induced generalized seizures by 
amino-oxy-acetic acid. Can J Physiol 
Pharmacol 58， 7-11. 
20) Lehmann， J.， Schneider， J.， McPherson，S.， 
Murphy， D. E.， Bernard， P.， Tsai， C.， 
Bennett， D. A.， Pastor， G.， Steel， D. J.， 
Boehm， c.， Cheney， D. L.， Liebman， J.M.， 
Williams， M. and Wood， P. L. (1987). 
CPP， a selective N -methy.1 D-aspartate 
(NMDA)-type receptor antagonist: Char-
acterization in vitro and vivo. J Phar-
macol Exp Ther 240， 737-746. 
21) Loscher， W.， N olting， B. and Honach， D. 
(1988). Evaluation of CPP， a selective 
NMDA antagonist， in various rodent 
models of epilepsy. Comparison with 
other NMDA antagonists， and with diaze命
pam and phenobarbital. Eur J Pharmacol 
152， 9-17. 
22) Lothman， E. W.， Bennett， J. P. and 
Perlin， J.B. (1987). Alterations in neuro櫛
transmitter amino acids in hippocampal 
kindled seizures. Epilepsy Res 1， 313-320. 
23) Meldrum， B. (1984). Amino acid neuro-
transmitters and new approaches to 
anticonvulsant drug action. Epilepsia 25， 
s140-149. 
24) Meldrum， B.， Millan， M.， Patel， S.and de 
Sarro， G. (1988). Anti-epileptic effects of 
focal micro-injection of excitatory amino 
acid antagonists. J N eural Transm 72， 191 
-200. 
25) Moreau， J -L.， Pieri， L. and Prud'hon， B. 
(1989). Convulsions induced by centrally 
administered NMDA in mice: effects of 
NMDA antagonists， benzodiazepines， 
minor tranquilizers and anticonvulsants. 
Br J Pharmacol 98， 1050-1054. 








28) Myslobodsky， M. S.， Ackermann， R. F. 
and Engel， J.Jr. (1979). Effects of γ-
acetylenic GABA and y-vinyl GABA on 
metrazol-activated， and kindled seizures. 
Pharmacol Biochem Behav 11， 265-271. 
29) Okazaki， M. M.， McNamara， J.O. and 
Nadler， J.V. (1989). N-methyl-D-aspar-
NMDAけいれん 15 
tate receptor autoradiography in rat brain 
after angular bundle kindling. Brain Res 
482， 359-364. 
30) Peterson， D. W.， Collins， J. F. and 
Bradford，日. F. (1983). The kindled 
amygdala model of epilepsy: anticonvul-
sant action of amino acid antagonists. 
Brain Res 275， 169-172. 
31) Peterson， D. W.， Collins， J. F. and 
Bradford， H. F. (1984). Anticonvulsant 
action of amino acid antagonists against 
kindled hippocampal seizures. Brain Res 
311， 176-180. 
32) Racine， R. J. (1972). Modification of 
seizure activity by electrical stimulation: 
I. 旺oter seizure. Electroenceph Clin 
Neurophysiol 32， 281-297. 
33) Rimmer， E. M. and Richens， A. (1984). 
Doubleblind study of γ-vinyl GABA in 
patients with refractory epilepsy. Lancet 
1， 189-190. 
34) Sato， K.， Morimoto， K. and Okamoto， M. 
(1988). Anticonvulsant action of a non-
competitive antagonist of NMDA 
receptors(MK -801) in. the kindling model 
of epilepsy. Brain Res 463， 12-20. 
35)佐藤光糠，森本清(1983).てんかんにかか
わる促進系と抑制系.神経進歩27巻， 578-588.
36)佐藤光源， Wada， J.A. (1975).新しい実験
てんかんモデルとしての"kindling"prepara得





38) Sawyer， C. H.， Everett. J. W. and Greem， 
J. D. (1954). The rabbit diencephalon in 
stereotaxic coordinates. J Comp Neurol 
101， 801-824. 
39) Schechter， P. ].， Hanke， N. F. ].， Grove， 
].， Huebert， N. and Sjoerdsma， A. (1984). 
Biochemical and clinical effects ofγ-vinyl 
GABA in patients with epilepsy. Neurol-
ogy 34， 182-186. 
40) Shin， C.， Rigsbee， L. G. and McNamara， 
J. O. (1986). Anti-seizure and anti-epile-
ptogenic effect of y-vinyl γ-aminobutylic 
acid in amygdaloid kindling. Brain Res 
398，370-37 4. 
41) Siegel， J. and Murphy， G. J. (1979). 
Serotonergic inhibition of amygdala-kin峨
dled seizures in cats. Brain Res 174， 337-
340. 
42) Stone， W. E. and Javid， M. J. (1983). 
Effects of anticonvulsants and other 
agents on seizures induced by intracere鮒




44) Troupin， A. S.， Mendius， J.R.， Cheng， F. 
and Risinger， M. W. (1986). 14. MK -801 
In: Current problems in epilepsy: 4 New 
anticonvulsant drugs， Ed. Meldrum， B. S. 
and Porter， R. ].， pp 191-201， J ohn 
Libbey， London. 
45) Turski， L.， Klockgether， T.， Sontag， K. 
H.， Herrling， P. L. and Watkins， J. C. 
(1987). Muscle relaxant and anticonvul-
sant activity of 3-(:t)-2-carboxypiper-
azin -4-yl)-propyl-1-phsphonic acid， a 
novel N-methyl-D-aspartate antagonist， 
in rodents. Neurosci Lett 73， 143-148. 
46) Watkins， J.C. (1984). Excitatory amino 
acids and central synaptic transmission. 
Treds Pharmacol 5， 373-376. 
47) Wong， E. H. F.， Kemp， J.A.， Priestley， 
T.， Knight， A. R.， Woodruff， G. N. and 
Iversen， L. L. (1986). The anticonvulsant 
MK-801 is a potent N-methyl-D-aspar-
tate antagonist. Proc N ath Acad Sci USA 
83，7104-7108. 
